Concepedia

Publication | Open Access

A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C

DOIFull Paper Access

64

Citations

30

References

2007

Year

Masao Omata, Haruhiko Yoshida, J. Toyota, Eiichi Tomita, S. Nishiguchi, Norio Hayashi, S Iino, Isao Makino, K Okita, G Toda,
Gut

Abstract

A 600 mg/day UDCA dose was optimal to decrease ALT and AST levels in CH-C patients. The 900 mg/day dose decreased GGT levels further, and may be preferable in patients with prevailing biliary injuries.

References

YearCitations

Page 1